Patent: 8,486,957
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 8,486,957
Title: | Chemotherapeutic for inducing an MSH2-dependent apoptotic pathway |
Abstract: | A method of treating cancer in a subject in need thereof comprises administering said subject reserpine, yohimbine, an analog thereof, or a pharmaceutically acceptable salt or prodrug thereof, in an amount effective to treat the cancer. Compounds and compositions useful for carrying out the method are also described. |
Inventor(s): | Salsbury, Jr.; Freddie R. (Winston-Salem, NC), Scarpinato; Karin D. (Clemmons, NC), King; S. Bruce (Walnut Cove, NC) |
Assignee: | Wake Forest University Health Sciences (Winston-Salem, NC) |
Application Number: | 12/711,306 |
Patent Claims: | see list of patent claims |
Details for Patent 8,486,957
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2027-08-24 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2027-08-24 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2027-08-24 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2027-08-24 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |